Abbott Reports Third-Quarter 2025 Results and Reaffirms Full-Year Guidance
- Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1
- Third-quarter GAAP diluted EPS of
$0.94 ; adjusted diluted EPS of$1.30 - Reported operating margin of 18.1 percent of sales; adjusted operating margin of 23.0 percent, which reflects a 40 basis point increase
- Third-quarter sales increased 6.9 percent on a reported basis, 5.5 percent on an organic basis, or 7.5 percent when excluding COVID-19 testing-related sales1.
- Third-quarter GAAP diluted EPS of
$0.94 and adjusted diluted EPS of$1.30 , which excludes specified items. - Year-to-date sales increased 6.1 percent on a reported basis, 6.4 percent on an organic basis, or 7.7 percent when excluding COVID-19 testing-related sales2.
Abbott reaffirms previously provided full-year 2025 organic sales growth guidance.Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to$5.12 to$5.18 , reflecting double-digit growth at the midpoint.- In July,
Abbott announced it received regulatory approval inJapan for TriClip®, a first of-its-kind, minimally invasive treatment option for patients with tricuspid regurgitation, or a leaky tricuspid heart valve. - In August,
Abbott announced it received CE Mark for an expanded indication for the company'sNavitor ® transcatheter aortic valve implantation (TAVI) system to treat people with symptomatic, severe aortic stenosis who are at low or intermediate risk for open-heart surgery. - In August, at the
European Society of Cardiology (ESC) Congress , new treatment guidelines were issued that provide additional support for the use of MitraClip® and TriClip in treating valvular heart disease. These new guidelines were backed by evidence from multiple clinical studies.
"Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance," said
THIRD-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.
Note: In order to compute results excluding the impact of exchange rates, current year
Third Quarter 2025 Results (3Q25) | |||||||||
Sales 3Q25 ($ in millions) | | Nutrition | Diagnostics | Established | Medical | ||||
4,299 | 888 | 886 | — | 2,521 | |||||
International | 7,070 | 1,265 | 1,367 | 1,511 | 2,927 | ||||
Total reported | 11,369 | 2,153 | 2,253 | 1,511 | 5,448 | ||||
% Change vs. 3Q24 | |||||||||
2.3 | (6.5) | (14.1) | n/a | 13.8 | |||||
International | 9.9 | 13.3 | (1.0) | 7.5 | 15.6 | ||||
Total reported | 6.9 | 4.2 | (6.6) | 7.5 | 14.8 | ||||
Impact of foreign exchange | 1.4 | 0.2 | 1.2 | 0.4 | 2.3 | ||||
Organic | 5.5 | 4.0 | (7.8) | 7.1 | 12.5 | ||||
Impact of COVID-19 testing sales 1 | (2.0) | — | (8.2) | — | — | ||||
Organic (excluding COVID-19 tests) | 7.5 | 4.0 | 0.4 | 7.1 | 12.5 | ||||
Organic | |||||||||
| 2.3 | (6.5) | (14.1) | n/a | 13.8 | ||||
International | 7.6 | 13.0 | (3.1) | 7.1 | 11.3 | ||||
First Nine Months 2025 Results (9M25) | |||||||||
Sales 9M25 ($ in millions) | | Nutrition | Diagnostics | Established | Medical | ||||
12,743 | 2,800 | 2,568 | — | 7,363 | |||||
International | 20,126 | 3,711 | 3,912 | 4,154 | 8,349 | ||||
Total reported | 32,869 | 6,511 | 6,480 | 4,154 | 15,712 | ||||
% Change vs. 9M24 | |||||||||
6.4 | 1.4 | (7.4) | n/a | 14.4 | |||||
International | 6.0 | 5.3 | (3.3) | 5.8 | 11.3 | ||||
Total reported | 6.1 | 3.6 | (5.0) | 5.8 | 12.8 | ||||
Impact of foreign exchange | (0.3) | (0.9) | (0.2) | (1.7) | 0.4 | ||||
Impact of business exit* | — | (0.2) | — | — | — | ||||
Organic | 6.4 | 4.7 | (4.8) | 7.5 | 12.4 | ||||
Impact of COVID-19 testing sales 2 | (1.3) | — | (5.4) | — | — | ||||
Organic (excluding COVID-19 tests) | 7.7 | 4.7 | 0.6 | 7.5 | 12.4 | ||||
Organic | |||||||||
| 6.5 | 1.9 | (7.4) | n/a | 14.4 | ||||
International | 6.4 | 6.9 | (3.0) | 7.5 | 10.7 | ||||
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.
*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in |
Nutrition | |||||
Third Quarter 2025 Results (3Q25) | |||||
Sales 3Q25 ($ in millions) | Total | Pediatric | Adult | ||
888 | 520 | 368 | |||
International | 1,265 | 457 | 808 | ||
Total reported | 2,153 | 977 | 1,176 | ||
% Change vs. 3Q24 | |||||
(6.5) | (8.4) | (3.8) | |||
International | 13.3 | 17.9 | 10.9 | ||
Total reported | 4.2 | 2.3 | 5.8 | ||
Impact of foreign exchange | 0.2 | (0.1) | 0.4 | ||
Organic | 4.0 | 2.4 | 5.4 | ||
| (6.5) | (8.4) | (3.8) | ||
International | 13.0 | 18.2 | 10.2 | ||
Worldwide Nutrition sales increased 4.2 percent on a reported basis and 4.0 percent on an organic basis in the third quarter.
Growth in the quarter was led by Adult Nutrition, where sales increased 5.8 percent on a reported basis and 5.4 percent on an organic basis, led by strong growth of Ensure®,
First Nine Months 2025 Results (9M25) | |||||
Sales 9M25 ($ in millions) | Total | Pediatric | Adult | ||
2,800 | 1,695 | 1,105 | |||
International | 3,711 | 1,377 | 2,334 | ||
Total reported | 6,511 | 3,072 | 3,439 | ||
% Change vs. 9M24 | |||||
1.4 | 3.0 | (0.9) | |||
International | 5.3 | — | 8.8 | ||
Total reported | 3.6 | 1.6 | 5.5 | ||
Impact of foreign exchange | (0.9) | (0.9) | (0.9) | ||
Impact of business exit* | (0.2) | — | (0.4) | ||
Organic | 4.7 | 2.5 | 6.8 | ||
| 1.9 | 3.0 | 0.3 | ||
International | 6.9 | 1.8 | 10.2 | ||
*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in |
Diagnostics | |||||||||
Third Quarter 2025 Results (3Q25) | |||||||||
Sales 3Q25 ($ in millions) | Total | | Molecular | Point of Care | Rapid | ||||
886 | 366 | 36 | 111 | 373 | |||||
International | 1,367 | 998 | 95 | 47 | 227 | ||||
Total reported | 2,253 | 1,364 | 131 | 158 | 600 | ||||
% Change vs. 3Q24 | |||||||||
(14.1) | 10.4 | (1.5) | 7.9 | (33.5) | |||||
International | (1.0) | 1.6 | 4.3 | 8.9 | (14.2) | ||||
Total reported | (6.6) | 3.8 | 2.6 | 8.2 | (27.3) | ||||
Impact of foreign exchange | 1.2 | 1.6 | 1.8 | 0.4 | 0.4 | ||||
Organic | (7.8) | 2.2 | 0.8 | 7.8 | (27.7) | ||||
| (14.1) | 10.4 | (1.5) | 7.9 | (33.5) | ||||
International | (3.1) | (0.6) | 1.7 | 7.7 | (15.6) | ||||
COVID-19 testing-related sales were
First Nine Months 2025 Results (9M25) | |||||||||
Sales 9M25 ($ in millions) | Total | | Molecular | Point of Care | Rapid | ||||
2,568 | 1,049 | 111 | 315 | 1,093 | |||||
International | 3,912 | 2,850 | 265 | 133 | 664 | ||||
Total reported | 6,480 | 3,899 | 376 | 448 | 1,757 | ||||
% Change vs. 9M24 | |||||||||
(7.4) | 8.3 | (0.5) | 2.4 | (21.2) | |||||
International | (3.3) | (1.0) | (2.7) | (0.1) | (12.9) | ||||
Total reported | (5.0) | 1.3 | (2.0) | 1.7 | (18.2) | ||||
Impact of foreign exchange | (0.2) | (0.3) | — | (0.1) | (0.2) | ||||
Organic | (4.8) | 1.6 | (2.0) | 1.8 | (18.0) | ||||
| (7.4) | 8.3 | (0.5) | 2.4 | (21.2) | ||||
International | (3.0) | (0.7) | (2.7) | 0.3 | (12.4) | ||||
| |||||
Third Quarter 2025 Results (3Q25) | |||||
Sales 3Q25 ($ in millions) | Total | Key Emerging | Other | ||
— | — | — | |||
International | 1,511 | 1,097 | 414 | ||
Total reported | 1,511 | 1,097 | 414 | ||
% Change vs. 3Q24 | |||||
n/a | n/a | n/a | |||
International | 7.5 | 10.3 | 0.6 | ||
Total reported | 7.5 | 10.3 | 0.6 | ||
Impact of foreign exchange | 0.4 | (0.8) | 3.1 | ||
Organic | 7.1 | 11.1 | (2.5) | ||
| n/a | n/a | n/a | ||
International | 7.1 | 11.1 | (2.5) | ||
Key
First Nine Months 2025 Results (9M25) | |||||
Sales 9M25 ($ in millions) | Total | Key Emerging | Other | ||
— | — | — | |||
International | 4,154 | 3,121 | 1,033 | ||
Total reported | 4,154 | 3,121 | 1,033 | ||
% Change vs. 9M24 | |||||
n/a | n/a | n/a | |||
International | 5.8 | 7.3 | 1.7 | ||
Total reported | 5.8 | 7.3 | 1.7 | ||
Impact of foreign exchange | (1.7) | (2.4) | 0.5 | ||
Organic | 7.5 | 9.7 | 1.2 | ||
| n/a | n/a | n/a | ||
International | 7.5 | 9.7 | 1.2 | ||
Medical Devices | |||||||||||||||
Third Quarter 2025 Results (3Q25) | |||||||||||||||
Sales 3Q25 ($ in millions) | Total | Rhythm | Electro- physiology | Heart | Vascular | Structural | Neuro- | Diabetes | |||||||
2,521 | 350 | 322 | 280 | 280 | 297 | 196 | 796 | ||||||||
International | 2,927 | 336 | 383 | 86 | 465 | 338 | 58 | 1,261 | |||||||
Total reported | 5,448 | 686 | 705 | 366 | 745 | 635 | 254 | 2,057 | |||||||
% Change vs. 3Q24 | |||||||||||||||
13.8 | 21.1 | 13.2 | 10.7 | 8.5 | 10.1 | 3.3 | 18.4 | ||||||||
International | 15.6 | 9.3 | 17.6 | 22.6 | 5.5 | 16.9 | 24.9 | 19.9 | |||||||
Total reported | 14.8 | 15.0 | 15.6 | 13.3 | 6.6 | 13.6 | 7.6 | 19.3 | |||||||
Impact of foreign exchange | 2.3 | 2.0 | 1.9 | 1.2 | 1.9 | 2.3 | 0.8 | 3.1 | |||||||
Organic | 12.5 | 13.0 | 13.7 | 12.1 | 4.7 | 11.3 | 6.8 | 16.2 | |||||||
| 13.8 | 21.1 | 13.2 | 10.7 | 8.5 | 10.1 | 3.3 | 18.4 | |||||||
International | 11.3 | 5.5 | 14.1 | 17.2 | 2.5 | 12.4 | 21.2 | 14.7 | |||||||
Worldwide Medical Devices sales increased 14.8 percent on a reported basis and 12.5 percent on an organic basis in the third quarter.
Sales growth in the quarter was led by double-digit growth in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure and Structural Heart.
In Diabetes Care, sales of continuous glucose monitors were
First Nine Months 2025 Results (9M25) | |||||||||||||||
Sales 9M25 ($ in millions) | Total | Rhythm | Electro- physiology | Heart | Vascular | Structural | Neuro- | Diabetes | |||||||
7,363 | 994 | 943 | 824 | 831 | 868 | 565 | 2,338 | ||||||||
International | 8,349 | 950 | 1,091 | 249 | 1,381 | 980 | 171 | 3,527 | |||||||
Total reported | 15,712 | 1,944 | 2,034 | 1,073 | 2,212 | 1,848 | 736 | 5,865 | |||||||
% Change vs. 9M24 | |||||||||||||||
14.4 | 16.7 | 12.2 | 12.4 | 5.6 | 14.1 | 0.3 | 23.2 | ||||||||
International | 11.3 | 3.9 | 10.9 | 15.9 | 4.2 | 11.8 | 20.6 | 15.9 | |||||||
Total reported | 12.8 | 10.1 | 11.5 | 13.2 | 4.7 | 12.9 | 4.4 | 18.7 | |||||||
Impact of foreign exchange | 0.4 | 0.4 | 0.2 | 0.3 | 0.1 | 0.4 | (0.1) | 0.6 | |||||||
Organic | 12.4 | 9.7 | 11.3 | 12.9 | 4.6 | 12.5 | 4.5 | 18.1 | |||||||
| 14.4 | 16.7 | 12.2 | 12.4 | 5.6 | 14.1 | 0.3 | 23.2 | |||||||
International | 10.7 | 3.2 | 10.5 | 14.6 | 4.0 | 11.2 | 20.8 | 14.9 | |||||||
On
About
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.
1. | In the third quarter of 2025, total worldwide sales were |
2. | In the first nine months of 2025, total worldwide sales were |
Condensed Consolidated Statement of Earnings Third Quarter Ended (in millions, except per share data) (unaudited) | ||||||
3Q25 | 3Q24 | % Change | ||||
6.9 | ||||||
Cost of products sold, excluding amortization expense | 5,075 | 4,698 | 8.0 | |||
Amortization of intangible assets | 420 | 470 | (10.8) | |||
Research and development | 766 | 713 | 7.5 | |||
Selling, general, and administrative | 3,051 | 2,895 | 5.4 | |||
Total Operating Cost and Expenses | 9,312 | 8,776 | 6.1 | |||
Operating Earnings | 2,057 | 1,859 | 10.6 | |||
Interest expense, net | 44 | 51 | (12.6) | |||
Net foreign exchange (gain) loss | (17) | (11) | n/m | |||
Other (income) expense, net | (150) | (121) | 23.7 | |||
Earnings before taxes | 2,180 | 1,940 | 12.3 | |||
Taxes on earnings | 536 | 294 | 82.0 | 1) | ||
Net Earnings | (0.1) | |||||
Net Earnings excluding Specified Items, as described below | 7.5 | 2) | ||||
Diluted Earnings per Common Share | — | |||||
Diluted Earnings per Common Share, excluding Specified Items, as described below | 7.4 | 2) | ||||
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,749 | 1,748 | ||||
NOTES: | |
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. | |
n/m = Percent change is not meaningful. | |
See footnotes on the following section. | |
1) | 2025 Taxes on Earnings also includes approximately |
2) | 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of |
2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of | |
Condensed Consolidated Statement of Earnings Nine Months Ended (in millions, except per share data) (unaudited) | ||||||
9M25 | 9M24 | % Change | ||||
6.1 | ||||||
Cost of products sold, excluding amortization expense | 14,397 | 13,764 | 4.6 | |||
Amortization of intangible assets | 1,260 | 1,413 | (10.8) | |||
Research and development | 2,207 | 2,095 | 5.4 | |||
Selling, general, and administrative | 9,203 | 8,790 | 4.7 | |||
Total Operating Cost and Expenses | 27,067 | 26,062 | 3.9 | |||
Operating Earnings | 5,802 | 4,914 | 18.1 | |||
Interest expense, net | 143 | 170 | (15.3) | |||
Net foreign exchange (gain) loss | (35) | (17) | n/m | |||
Other (income) expense, net | (414) | (222) | 86.8 | |||
Earnings before taxes | 6,108 | 4,983 | 22.6 | |||
Taxes on earnings | 1,360 | 810 | 67.7 | 1) | ||
Net Earnings | 13.8 | |||||
Net Earnings excluding Specified Items, as described below | 9.6 | 2) | ||||
Diluted Earnings per Common Share | 13.4 | |||||
Diluted Earnings per Common Share, excluding Specified Items, as described below | 9.6 | 2) | ||||
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,749 | 1,749 | ||||
NOTES: | |
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information. | |
n/m = Percent change is not meaningful. | |
See footnotes on the following section. | |
1) | 2025 Taxes on Earnings includes the recognition of approximately |
2024 Taxes on Earnings includes the recognition of approximately | |
2) | 2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of |
2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of | |
Non-GAAP Reconciliation of Financial Information Third Quarter Ended (in millions, except per share data) (unaudited) | |||||
3Q25 | |||||
As Reported | Specified | As Adjusted | |||
Intangible Amortization | $ 420 | $ (420) | $ — | ||
Gross Margin | 5,874 | 470 | 6,344 | ||
R&D | 766 | (36) | 730 | ||
SG&A | 3,051 | (47) | 3,004 | ||
Other (income) expense, net | (150) | 5 | (145) | ||
Earnings before taxes | 2,180 | 548 | 2,728 | ||
Taxes on Earnings | 536 | (86) | 450 | ||
Net Earnings | 1,644 | 634 | 2,278 | ||
Diluted Earnings per Share | $ 0.94 | $ 0.36 | $ 1.30 | ||
Specified items reflect intangible amortization expense of $420 million and other net expenses of $128 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
3Q24 | |||||
As Reported | Specified | As Adjusted | |||
Intangible Amortization | $ 470 | $ (470) | $ — | ||
Gross Margin | 5,467 | 516 | 5,983 | ||
R&D | 713 | (19) | 694 | ||
SG&A | 2,895 | (5) | 2,890 | ||
Other (income) expense, net | (121) | (12) | (133) | ||
Earnings before taxes | 1,940 | 552 | 2,492 | ||
Taxes on Earnings | 294 | 79 | 373 | ||
Net Earnings | 1,646 | 473 | 2,119 | ||
Diluted Earnings per Share | $ 0.94 | $ 0.27 | $ 1.21 | ||
Specified items reflect intangible amortization expense of $470 million and other net expenses of $82 million associated with charges related to intangible impairment, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
Non-GAAP Reconciliation of Financial Information Nine Months Ended September 30, 2025 and 2024 (in millions, except per share data) (unaudited) | |||||
9M25 | |||||
As Reported | Specified | As Adjusted | |||
Intangible Amortization | $ 1,260 | $ (1,260) | $ — | ||
Gross Margin | 17,212 | 1,396 | 18,608 | ||
R&D | 2,207 | (83) | 2,124 | ||
SG&A | 9,203 | (58) | 9,145 | ||
Other (income) expense, net | (414) | (31) | (445) | ||
Earnings before taxes | 6,108 | 1,568 | 7,676 | ||
Taxes on Earnings | 1,360 | (94) | 1,266 | ||
Net Earnings | 4,748 | 1,662 | 6,410 | ||
Diluted Earnings per Share | $ 2.70 | $ 0.95 | $ 3.65 | ||
Specified items reflect intangible amortization expense of $1.260 billion and other net expenses of $308 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
9M24 | |||||
As Reported | Specified Items | As Adjusted | |||
Intangible Amortization | $ 1,413 | $ (1,413) | $ — | ||
Gross Margin | 15,799 | 1,540 | 17,339 | ||
R&D | 2,095 | (81) | 2,014 | ||
SG&A | 8,790 | (96) | 8,694 | ||
Other (income) expense, net | (222) | (183) | (405) | ||
Earnings before taxes | 4,983 | 1,900 | 6,883 | ||
Taxes on Earnings | 810 | 222 | 1,032 | ||
Net Earnings | 4,173 | 1,678 | 5,851 | ||
Diluted Earnings per Share | $ 2.38 | $ 0.95 | $ 3.33 | ||
Specified items reflect intangible amortization expense of $1.413 billion and other net expenses of $487 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.
A reconciliation of the third-quarter tax rates for 2025 and 2024 is shown below:
3Q25 | ||||||
($ in millions) | Pre-Tax Income | Taxes on Earnings | Tax Rate | |||
As reported (GAAP) | $ 2,180 | $ 536 | 24.6 % | 1) | ||
Specified items | 548 | (86) | ||||
Excluding specified items | $ 2,728 | $ 450 | 16.5 % | |||
3Q24 | ||||||
($ in millions) | Pre-Tax Income | Taxes on Earnings | Tax Rate | |||
As reported (GAAP) | $ 1,940 | $ 294 | 15.2 % | |||
Specified items | 552 | 79 | ||||
Excluding specified items | $ 2,492 | $ 373 | 15.0 % | |||
1) | 2025 Taxes on Earnings also includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. |
A reconciliation of the year-to-date tax rates for 2025 and 2024 is shown below:
9M25 | ||||||
($ in millions) | Pre-Tax Income | Taxes on Earnings | Tax Rate | |||
As reported (GAAP) | $ 6,108 | $ 1,360 | 22.3 % | 2) | ||
Specified items | 1,568 | (94) | ||||
Excluding specified items | $ 7,676 | $ 1,266 | 16.5 % | |||
9M24 | ||||||
($ in millions) | Pre-Tax Income | Taxes on Earnings | Tax Rate | |||
As reported (GAAP) | $ 4,983 | $ 810 | 16.3 % | 3) | ||
Specified items | 1,900 | 222 | ||||
Excluding specified items | $ 6,883 | $ 1,032 | 15.0 % | |||
2) | 2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. |
3) | 2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years. |
Non-GAAP Revenue Reconciliation Nine Months Ended September 30, 2025 and 2024 ($ in millions) (unaudited) | |||||||||||
9M25 | 9M24 | % Change vs. 9M24 | |||||||||
Non-GAAP | |||||||||||
|
| Impact | Adjusted | Reported | Adjusted | Organic | |||||
Total Company | 32,869 | 30,976 | (13) | 30,963 | 6.1 | 6.1 | 6.4 | ||||
12,743 | 11,982 | (13) | 11,969 | 6.4 | 6.5 | 6.5 | |||||
Intl | 20,126 | 18,994 | — | 18,994 | 6.0 | 6.0 | 6.4 | ||||
Total Nutrition | 6,511 | 6,284 | (13) | 6,271 | 3.6 | 3.8 | 4.7 | ||||
2,800 | 2,761 | (13) | 2,748 | 1.4 | 1.9 | 1.9 | |||||
Intl | 3,711 | 3,523 | — | 3,523 | 5.3 | 5.3 | 6.9 | ||||
Adult Nutrition | 3,439 | 3,261 | (13) | 3,248 | 5.5 | 5.9 | 6.8 | ||||
1,105 | 1,115 | (13) | 1,102 | (0.9) | 0.3 | 0.3 | |||||
Intl | 2,334 | 2,146 | — | 2,146 | 8.8 | 8.8 | 10.2 | ||||
(a) | Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business. This action was initiated in March 2024. |
Details of Specified Items Third Quarter Ended September 30, 2025 (in millions, except per share data) (unaudited) | |||||||||
Acquisition or Divestiture- related (a) | Restructuring and Cost Reduction Initiatives (b) | Intangible Amortization | Other (c) | Total Specifieds | |||||
Gross Margin | $ — | $ 44 | $ 420 | $ 6 | $ 470 | ||||
R&D | — | (19) | — | (17) | (36) | ||||
SG&A | (9) | (43) | — | 5 | (47) | ||||
Other (income) expense, net | 7 | — | — | (2) | 5 | ||||
Earnings before taxes | $ 2 | $ 106 | $ 420 | $ 20 | 548 | ||||
Taxes on Earnings (d) | (86) | ||||||||
Net Earnings | $ 634 | ||||||||
Diluted Earnings per Share | $ 0.36 | ||||||||
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." | |
a) | Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses. |
b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
c) | Other includes incremental costs to comply with the |
d) | Reflects the net tax benefit associated with the specified items. Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. |
Details of Specified Items Third Quarter Ended September 30, 2024 (in millions, except per share data) (unaudited) | |||||||||
Acquisition or Divestiture- related (a) | Restructuring and Cost Reduction Initiatives (b) | Intangible Amortization | Other (c) | Total Specifieds | |||||
Gross Margin | $ — | $ 2 | $ 470 | $ 44 | $ 516 | ||||
R&D | — | — | — | (19) | (19) | ||||
SG&A | (7) | 2 | — | — | (5) | ||||
Other (income) expense, net | (5) | — | — | (7) | (12) | ||||
Earnings before taxes | $ 12 | $ — | $ 470 | $ 70 | 552 | ||||
Taxes on Earnings (d) | 79 | ||||||||
Net Earnings | $ 473 | ||||||||
Diluted Earnings per Share | $ 0.27 | ||||||||
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." | |
a) | Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses. |
b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
c) | Other includes incremental costs to comply with the |
d) | Reflects the net tax benefit associated with the specified items. |
Abbott Laboratories and Subsidiaries Details of Specified Items Nine Months Ended September 30, 2025 (in millions, except per share data) (unaudited) | |||||||||
Acquisition or Divestiture- related (a) | Restructuring and Cost Reduction Initiatives (b) | Intangible Amortization | Other (c) | Total Specifieds | |||||
Gross Margin | $ 1 | $ 125 | $ 1,260 | $ 10 | $ 1,396 | ||||
R&D | (1) | (42) | — | (40) | (83) | ||||
SG&A | (15) | (49) | — | 6 | (58) | ||||
Other (income) expense, net | (18) | — | — | (13) | (31) | ||||
Earnings before taxes | $ 35 | $ 216 | $ 1,260 | $ 57 | 1,568 | ||||
Taxes on Earnings (d) | (94) | ||||||||
Net Earnings | $ 1,662 | ||||||||
Diluted Earnings per Share | $ 0.95 | ||||||||
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." | |
a) | Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. |
b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
c) | Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments. |
d) | Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. |
Details of Specified Items Nine Months Ended September 30, 2024 (in millions, except per share data) (unaudited) | |||||||||
Acquisition or Divestiture- related (a) | Restructuring and Cost Reduction Initiatives (b) | Intangible Amortization | Other (c) | Total Specifieds | |||||
Gross Margin | $ 2 | $ 76 | $ 1,413 | $ 49 | $ 1,540 | ||||
R&D | (4) | (1) | — | (76) | (81) | ||||
SG&A | (32) | (17) | — | (47) | (96) | ||||
Other (income) expense, net | (140) | — | — | (43) | (183) | ||||
Earnings before taxes | $ 178 | $ 94 | $ 1,413 | $ 215 | 1,900 | ||||
Taxes on Earnings (d) | 222 | ||||||||
Net Earnings | $ 1,678 | ||||||||
Diluted Earnings per Share | $ 0.95 | ||||||||
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." | |
a) | Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions. |
b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. |
c) | Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments. |
d) | Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years. |
View original content:https://www.prnewswire.com/news-releases/
SOURCE
Abbott Financial: Michael Comilla, 224-668-1872, Tamika McLoughlin, 224-399-5082, Randy Blakley, 224-668-0036, or Abbott Media: Karen Twigg May, 224-668-2681, Kate Dyer, 224-668-9965
